TACTI-004 trial

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Editorial infographic showing an AI data center, semiconductor fab and industrial water-treatment systems, with highlights on water audits, reuse infrastructure, treatment contracts and cooling efficiency.

Is water becoming the next infrastructure bottleneck for AI and chip factories?

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Why Immutep Limited halted its lung cancer trial and how the decision reshapes its immunotherapy strategy (NASDAQ: IMMP)

Immutep Limited halts the TACTI-004 Phase III lung cancer trial. Discover what the futility result means for eftilagimod alfa and LAG-3 immunotherapy.

μFR system
αvβ6-integrin
α4β7 integrin
Þorgerður Katrín Gunnarsdóttir
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynyz
ZYNRELEF

March 16, 2026